Table 2.
Outcomes of the Three Groups (Intention-to-Treat Population)
| Outcome | LPV/r | Arbidol | Control | p Value |
|---|---|---|---|---|
| Rate of positive-to-negative conversion of SARS-CoV-2 nucleic acid by pharyngeal swab (%) at day 7 | 12/34 (35.3%) | 13/35 (37.1%) | 7/17 (41.2%) | 0.966 |
| Rate of positive-to-negative conversion of SARS-CoV-2 nucleic acid by pharyngeal swab (%) at day 14 |
29/34 (85.3%) | 32/35 (91.4%) | 13/17 (76.5%) | 0.352 |
| Time of positive-to-negative conversion of SARS-CoV-2 nucleic acid in pharyngeal swab, in days (mean/SD, 95% CI) | 9.0 (5.0), (7.2, 10.8) | 9.1(4.4), (7.6, 10.6) | 9.3(5.2), (6.7, 11.9) | 0.981 |
| Conversion rate from moderate to severe/critical clinical status (%) | 8/34 (23.5%) | 3/35 (8.6%) | 2/17 (11.8%) | 0.206 |
| 7 days after initiating treatment | ||||
| Antipyresis rate (%) | 20/27 (74.1%) | 18/22 (81.8%) | 8/9 (88.9%) | 0.579 |
| Rate of cough alleviation (%) | 9/21 (42.9%) | 7/25 (28.0%) | 2/9 (22.2%) | 0.432 |
| Rate of improvement on chest CT (%) | 11/28 (39.3%) | 13/33 (39.4%) | 6/14 (42.9%) | 0.971 |
| 14 days after initiating treatment | ||||
| Antipyresis rate (%) | 24/27 (88.9%) | 21/22 (95.5%) | 9/9 (100%) | 0.343 |
| Rate of cough alleviation (%) | 16/21 (76.2%) | 14/25 (56.0%) | 4/9 (44.4%) | 0.180 |
| Rate of improvement on chest CT (%) | 21/28 (75.0%) | 23/33 (69.7%) | 13/14 (92.9%) | 0.089 |